home / stock / phvs / phvs quote
Last: | $20.35 |
---|---|
Change Percent: | 0.05% |
Open: | $21.7 |
Close: | $20.35 |
High: | $21.7 |
Low: | $19.53 |
Volume: | 33,049 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$20.35 | $21.7 | $20.35 | $21.7 | $19.53 | 33,049 | 05-17-2024 |
$21.71 | $22.1 | $21.71 | $24.11 | $21.36 | 14,213 | 05-16-2024 |
$22.1 | $21.1 | $22.1 | $23.07 | $21.1 | 60,954 | 05-15-2024 |
$20.8 | $21.56 | $20.8 | $21.56 | $20.7 | 17,452 | 05-14-2024 |
$21.17 | $21.68 | $21.17 | $22.135 | $20.75 | 22,529 | 05-13-2024 |
$21.46 | $20.79 | $21.46 | $21.52 | $20.14 | 66,628 | 05-10-2024 |
$20.57 | $20.72 | $20.57 | $20.86 | $20.33 | 23,166 | 05-09-2024 |
$20.85 | $22.36 | $20.85 | $22.575 | $20.59 | 27,497 | 05-08-2024 |
$22.62 | $22.59 | $22.62 | $23.13 | $21.69 | 45,524 | 05-07-2024 |
$22.68 | $22.95 | $22.68 | $24.02 | $21.875 | 56,526 | 05-06-2024 |
$22.6 | $23.77 | $22.6 | $23.9 | $22.475 | 55,488 | 05-03-2024 |
$23.53 | $24.685 | $23.53 | $25.5 | $23.49 | 78,777 | 05-02-2024 |
$24.57 | $24.01 | $24.57 | $25.16 | $23.16 | 114,135 | 05-01-2024 |
$24.59 | $23.25 | $24.59 | $25.2 | $23.25 | 67,926 | 04-30-2024 |
$23.45 | $23.35 | $23.45 | $24.15 | $22.55 | 49,577 | 04-29-2024 |
$23.35 | $22.56 | $23.35 | $25.44 | $22.2 | 85,067 | 04-26-2024 |
$22.77 | $20.74 | $22.77 | $24 | $19.59 | 82,367 | 04-25-2024 |
$21.25 | $21.45 | $21.25 | $22.715 | $21.02 | 34,153 | 04-24-2024 |
$21.29 | $20.85 | $21.29 | $24.2 | $20.54 | 88,778 | 04-23-2024 |
$20.87 | $19.5 | $20.87 | $20.87 | $17.57 | 50,601 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Pharvaris N.V. Company Name:
PHVS Stock Symbol:
NASDAQ Market:
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradyk...
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation ...
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrolling End-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis of HAE attacks Executing from a strong financial position with cash a...